OrthoCyte Corporation was formed in 2010 and is developing cellular therapeutics for orthopedic disorders. OrthoCyte’s lead project is the development of human embryonic progenitor (hEP) cell lines for cartilage repair, including osteoarthritis. OrthoCyte has identified several ACTCellerate™ cell lines that display potential to differentiate into diverse types of cartilage, and these lines are showing promising results in animal preclinical testing for effectiveness of cartilage repair. Our current goal is to demonstrate safety and efficacy of the cells using in vivo models of articular disease. If our studies in animal models prove successful, we would plan to initiate an IND filing with the FDA for this application.
